Yale study finds Ozempic recruits AgRP neurons to sustain fat loss
This digest was compiled by AI from multiple sources — links to the originals are below.
A Yale study published in Proceedings of the National Academy of Sciences found that semaglutide, the active ingredient in Ozempic, recruits AgRP hunger neurons to help maintain fat loss in a mouse model. The findings challenge the long-standing view that AgRP neurons work mainly against weight loss. First author Mateus d'Ávila said the research opens an avenue for developing more efficient obesity drugs.
Key Facts
- Yale researchers combined several experimental approaches while tracking body weight, food consumption, metabolism, and energy expenditure during semaglutide treatment in mice.
- They used genetic techniques to selectively eliminate or silence AgRP hunger neurons to test whether those neurons were required for semaglutide's lasting effects.
- Semaglutide, the active ingredient in GLP-1 medications such as Ozempic, can produce sustained weight loss of 10 to 15% or more.
- Earlier generations of weight loss medications reduce appetite nearly as effectively as semaglutide, yet do not produce the same level of sustained weight loss.
- The research was published in the journal Proceedings of the National Academy of Sciences (PNAS).
AgRP Neuron Mechanism
For decades, medications for obesity typically delivered only modest reductions in body weight. The arrival of Ozempic and other GLP-1 therapies changed that, producing sustained weight loss of 10 to 15% or more. Scientists had generally thought that AgRP neurons, known for stimulating hunger, worked mainly against weight loss. Yale researchers found that during treatment with GLP-1 drugs such as Ozempic, these neurons are recruited to help maintain fat loss. "This completely changes how we think about the mechanism involved in these medications and provides new insight into the biology underlying their long-term effects, opening an avenue for the development of more efficient drugs," said Mateus d'Ávila, first author of the study.
Study Design
The Yale team used a mouse model and combined several experimental approaches while tracking body weight, food consumption, metabolism, and energy expenditure during semaglutide treatment. They also used genetic techniques that allowed them to selectively eliminate or silence AgRP hunger neurons. This enabled the scientists to test whether those neurons were actually required for semaglutide to produce its lasting effects. Earlier generations of weight loss medications can reduce appetite nearly as effectively as semaglutide, yet they do not produce the same level of sustained weight loss. That difference led the Yale team to suspect that semaglutide must be doing more than simply making people or animals eat less.
1 source
Yale study finds Ozempic recruits AgRP neurons to sustain fat loss
